Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector (NAVIGATOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03279484
Recruitment Status : Active, not recruiting
First Posted : September 12, 2017
Last Update Posted : September 17, 2019
Sponsor:
Information provided by (Responsible Party):
MicroPort CRM

Brief Summary:
The primary objective of this study is to assess the safety and electrical performance of Left ventricular (LV) NAVIGO 4LV leads, pre-shaped (S-shaped&U-shaped: NAVIGO 4LV 2D, NAVIGO 4LV ARC) and Straight (NAVIGO 4LV PILOT), with IS4 connector

Condition or disease Intervention/treatment Phase
Arrythmia, Implatable Cardioverter Defibrillation, Lead Device: NAVIGO 4LV lead implant Not Applicable

Detailed Description:

The devices under investigation, NAVIGO 4LV models Pilot, 2D , and ARC are the new quadripolar coronary venous leads with polyurethane lead body, intended to be used with defibrillators with ventricular resynchronization therapy.

The new lead design with the presence of 4 electrodes that allows several combinations in programming pacing vectors, is intended to benefit both the patients by improving response to therapy, overcoming high pacing threshold and avoiding phrenic nerve stimulation, and the investigators by reducing the number of re-interventions needed.

This clinical investigation is a pre-market release study intended to analyze safety and electrical performance of NAVIGO 4LV leads pre-shaped (S-shaped & U-shaped) and Straight leads models. The primary endpoint data will be used to support the achievement of the CE mark of NAVIGO 4LV leads.

The primary endpoints will be evaluated at 1 month post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. The duration of patient inclusion will be approximately 10 months for pre-shaped NAVIGO family (S-shaped &U-shaped) and approximately 21 months for straight ones.

The post implant follows-up visits will take place at Hospital discharge, weeks 10, 6 months and every 6 months until 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 317 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

NAVIGO 4LV LV leads are available as "S shaped"(NAVIGO 4LV 2D) , "U shaped" (NAVIGO 4LV ARC) and "straight"( NAVIGO 4LV Pilot) models. All the models are available in 78 cm and 88 cm long versions. All models are designed for multipolar pacing (4 electrodes) and all of them have a quadripolar IS4 connector (IS4_LLLL).

The NAVIGO 4LV leads are steroid eluting to avoid adverse effects due to inflammation reaction of the myocardium after positioning of the lead, and therefore to limit the acute pacing threshold peak. The steroid collar design is the same as the one used in all other LIVANOVA leads

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector
Actual Study Start Date : November 24, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Experimental: NAVIGO 4LV implant
All patients will be attempted to implant or implanted with NAVIGO 4LV lead
Device: NAVIGO 4LV lead implant
All patients will be attempted to implant or implanted with NAVIGO 4LV lead




Primary Outcome Measures :
  1. LV lead Safety at 10 weeks [ Time Frame: 10 weeks after implant ]
    Freedom from LV lead-related complications, defined as any investigational device deficiency or any serious adverse device event (SADE) that resulted in patient death or required a re-intervention (not including re-programming) that occurred within 30 days after successful implant of the CRT-D system

  2. LV lead Performance at 10 weeks [ Time Frame: 10 weeks after implant ]
    Successful performance defined as LV pacing threshold at 10 weeks < 2.5 V/0.5 ms observed on at least one pacing vector and absence of phrenic nerve stimulation at programmed pacing amplitude


Secondary Outcome Measures :
  1. Electrical performance [ Time Frame: through study completion, an average of 6 month ]
    LV pacing threshold amplitude (V) and LV pacing impedance (Ohm)

  2. Rate of patients free from LV lead-related complications [ Time Frame: through study completion, an average of 6 month ]
    Freedom from LV lead-related complications defined as any investigational device deficiency or any serious adverse device event (SADE) that resulted in patient death or required a re-intervention (not including re-programming)

  3. LV lead-related SAEs [ Time Frame: through study completion, an average of 6 month ]
    Serious Adverse Event LV related

  4. Lead handing assessment of NAVIGO 4LV leads through a questionnaire [ Time Frame: Implant ]
    A questionnaire on lead handling will track opinion from the investigator, comparing his assessment with this lead to device he is accustomed to implant

  5. NAVIGO 4LV lead implant success rate on enrolled population [ Time Frame: Enrollment ]
    To report the NAVIGO 4LV lead implant success rate

  6. Number of patients with at least 2 pacing vectors with pacing threshold < 2.5 V at 0.5 ms and no phrenic nerve stimulation [ Time Frame: 10 weeks ]
    To report the number of patients with at least 2 pacing vectors with pacing threshold < 2.5 V at 0.5 ms and no phrenic nerve stimulation

  7. Number of patients with MP pacing activated [ Time Frame: through study completion, an average of 6 month ]
    To report the number of patients with MP pacing activated

  8. Rationale to activate MP [ Time Frame: through study completion, an average of 6 month ]
    To report the reason why physician decide to activate MP to the patient

  9. Number of patients with of at least one MP configuration with no phrenic nerve stimulation at programmed pacing amplitude [ Time Frame: through study completion, an average of 6 month ]
    To report the number of patients with at least one MP configuration with no phrenic nerve stimulation at programmed pacing amplitude

  10. Number of patients at each final programmed pacing vector and changes [ Time Frame: through study completion, an average of 6 month ]
    To report number of patients at each final programmed pacing vector and changes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any patient presenting a CRT-D indication as detailed in the ESC guidelines
  • Primary implant of a PLATINIUM 4LV CRTD or upgrade from an existing ICD connected to a RV lead with a DF4 connector (DF4LLHH) to a PLATINIUM 4LV CRT-D
  • Signed and dated informed consent

Exclusion Criteria:

  • Patients for whom a maximum single dose of 300 µg dexamethasone sodium phosphate (DSP) eluted from the NAVIGO 4LV lead maybe contraindicated
  • Venous anomalies precluding transvenous implant (contraindication of a Pacemaker or ICD implant)
  • Active myocarditis, pocket and/or lead infection
  • Stroke/myocardiaI infarction one month prior to implant
  • Already included in another clinical study that could confound the results of this study.
  • Inability to meet Follow-up visits at the implanting centre as defined in the investigational plan.
  • Patient less than 18 years old or under guardianship
  • Known pregnancy, women in lactation period or in childbearing age without an adequate contraceptive method (failure rate < 1%)
  • Drug addiction or abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03279484


Locations
Show Show 38 study locations
Sponsors and Collaborators
MicroPort CRM
Investigators
Layout table for investigator information
Principal Investigator: Juan Gabriel Martinez Martinez Hospital General Universitario Alicante Spain
Layout table for additonal information
Responsible Party: MicroPort CRM
ClinicalTrials.gov Identifier: NCT03279484    
Other Study ID Numbers: LCPL01
First Posted: September 12, 2017    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MicroPort CRM:
safety , electrical performance
Additional relevant MeSH terms:
Layout table for MeSH terms
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes